
    
      This is an open label trial.

      The study is designed to assess the efficacy and safety of 30 mg subcutaneous ecallantide in
      the treatment of acute attacks of hereditary angioedema. This study is designed to provide
      efficacy and safety data on repeated use of ecallantide. These data are intended to support
      the marketing authorization of ecallantide in the treatment of acute attacks of hereditary
      angioedema. Efficacy and safety of ecallantide will be evaluated in this study.
    
  